Long-term use of Lacticaseibacillus paracasei N1115 from early life alleviates high-fat-diet-induced obesity and dysmetabolism in mice
In: Beneficial MicrobesSearch for other papers by Z.H. Miao in
Current site
Google Scholar
Search for other papers by J.N. Wang in
Current site
Google Scholar
Search for other papers by X. Shen in
Current site
Google Scholar
Search for other papers by Q.Q. Zhou in
Current site
Google Scholar
Search for other papers by Y.T. Luo in
Current site
Google Scholar
Search for other papers by H.J. Liang in
Current site
Google Scholar
Search for other papers by S.J Wang in
Current site
Google Scholar
Search for other papers by S.H. Qi in
Current site
Google Scholar
Search for other papers by R.Y. Cheng in
Current site
Google Scholar
Search for other papers by F. He in
Current site
Google Scholar
Obesity has become one of the most serious public health problems worldwide, and an increasing number of studies indicate that the gut microbiota can affect host metabolism. Therefore, the present study was conducted to evaluate whether long-term use of probiotics can alleviate host obesity and metabolism by altering gut microbiota. The high-fat diet (HFD) starting from weaned period led to higher levels of visceral fat and a significantly heavier liver in male mice. Moreover, HFD resulted in disorders of glucose and lipid metabolism, changes in insulin-resistance indices (IR), and an increase in serum insulin and leptin in mice. Of note, 15 weeks use of Lacticaseibacillus paracasei N1115 decreased visceral fat, liver weight, serum levels of insulin and leptin, and IR and alleviated lipid dysmetabolism. HFD resulted in a significant increase in the relative abundance of Bilophila, Lachnoclostridium, and Blautia and may decrease the faecal short-chain fatty acid (SCFA) levels in mice; in turn, treatment with the potential probiotic strain L. paracasei N1115 protected mice from these negative effects. HFD significant impaired the physiology of the host especially in male mice and dramatically changed the composition of host gut microbiota. However, the use of potential probiotic strain, such as L. paracasei N1115, may prevent these impairments due to HFD via effecting the host gut microbiota and SCFA.
-
Amengual-Cladera, E., Llado, I., Gianotti, M. and Proenza, A.M., 2012. Sex differences in the effect of high-fat diet feeding on rat white adipose tissue mitochondrial function and insulin sensitivity. Metabolism 61: 1108-1117. https://doi.org/10.1016/j.metabol.2011.12.016
-
Beale, E.G. 2013. Insulin signaling and insulin resistance. Journal of Investigative Medicine 61: 11-14. https://doi.org/10.2310/JIM.0b013e3182746f95
-
Bluher, M., 2019. Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology 15: 288-298. https://doi.org/10.1038/s41574-019-0176-8
-
Boulange, C.L., Neves, A.L., Chilloux, J., Nicholson, J.K. and Dumas, M.E., 2016. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Medicine 8: 42. https://doi.org/10.1186/s13073-016-0303-2
-
Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z.J.Z., Downes, M.R., Evans, R.M., Brenner, D.A., Sirlin, C.B., Knight, R. and Loomba, R., 2019. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nature Communications 10: 1406. https://doi.org/10.1038/s41467-019-09455-9
-
Chawla, S., Tessarolo Silva, F., Amaral Medeiros, S., Mekary, R.A. and Radenkovic, D., 2020. The effect of low-fat and low-carbohydrate diets on weight loss and lipid levels: a systematic review and meta-analysis. Nutrients 12: 3774. https://doi.org/10.3390/nu12123774
-
Chen, H.R., Guan, K.F., Qi, X.F., Wang, R.C. and Ma, Y., 2020. alpha-Lactalbumin ameliorates hepatic lipid metabolism in high-fat-diet induced obese C57BL/6J mice. Journal of Functional Foods 75: 104253. https://doi.org/10.1016/j.jff.2020.104253
-
Chu, H.K., Duan, Y., Yang, L. and Schnabl, B., 2019. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut 68: 359-370. https://doi.org/10.1136/gutjnl-2018-316307
-
Cox, L.M., Yamanishi, S., Sohn, J., Alekseyenko, A.V., Leung, J.M., Cho, I., Kim, S.G., Li, H., Gao, Z., Mahana, D., Zarate Rodriguez, J.G., Rogers, A.B., Robine, N., Loke, P. and Blaser, M.J., 2014. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 158: 705-721. https://doi.org/10.1016/j.cell.2014.05.052
-
Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N.M., de Barsy, M., Loumaye, A., Hermans, M.P., Thissen, J.P., de Vos, W.M. and Cani, P.D., 2019. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine 25: 1096-1103. https://doi.org/10.1038/s41591-019-0495-2
-
Freire-Regatillo, A., Fernandez-Gomez, M.J., Diaz, F., Barrios, V., Sanchez-Jabonero, I., Frago, L.M., Argente, J., Garcia-Segura, L.M. and Chowen, J.A., 2020. Sex differences in the peripubertal response to a short-term, high-fat diet intake. Journal of Neuroendocrinology 32: e12756. https://doi.org/10.1111/jne.12756
-
Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D.B., Morgun, A. and Shulzhenko, N., 2020. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51: 102590. https://doi.org/10.1016/j.ebiom.2019.11.051
-
Hage, M.P. and Azar, S.T., 2014. Treating low high-density lipoprotein cholesterol: what is the evidence? Therapeutic Advances in Endocrinology and Metabolism 5: 10-17. https://doi.org/10.1177/2042018813517522
-
He, C., Cheng, D., Peng, C., Li, Y., Zhu, Y. and Lu, N., 2018. High-fat diet induces dysbiosis of gastric microbiota prior to gut microbiota in association with metabolic disorders in mice. Frontiers in Microbiology 9: 639. https://doi.org/10.3389/fmicb.2018.00639
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11: 506-514. https://doi.org/10.1038/nrgastro.2014.66
-
Huang, K.P., Ronveaux, C.C., Knotts, T.A., Rutkowsky, J.R., Ramsey, J.J. and Raybould, H.E., 2020. Sex differences in response to short-term high fat diet in mice. Physiology and Behaviour 221: 112894. https://doi.org/10.1016/j.physbeh.2020.112894
-
Jin, J., Cheng, R., Ren, Y., Shen, X., Wang, J., Xue, Y., Zhang, H., Jia, X., Li, T., He, F. and Tian, H., 2021. Distinctive gut microbiota in patients with overweight and obesity with dyslipidemia and its responses to long-term orlistat and ezetimibe intervention: a randomized controlled open-label trial. Frontiers in Pharmacology 12: 732541. https://doi.org/10.3389/fphar.2021.732541
-
John, G.K. and Mullin, G.E., 2016. The gut microbiome and obesity. Current Oncology Reports 18: 45. https://doi.org/10.1007/s11912-016-0528-7
-
Kimura, I., Ichimura, A., Ohue-Kitano, R. and Igarashi, M., 2020. Free Fatty Acid Receptors in Health and Disease. Physiol Rev 100: 171-210. https://doi.org/10.1152/physrev.00041.2018
-
Kitade, H., Chen, G.L., Ni, Y.H. and Ota, T., 2017. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients 9: 387. https://doi.org/10.3390/nu9040387
-
Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J.M., Rizkalla, S., Schrezenmeir, J. and Clement, K., 2019. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 9: e017995. https://doi.org/10.1136/bmjopen-2017-017995
-
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.M., Kennedy, S., Leonard, P., Li, J., Burgdorf, K., Grarup, N., Jorgensen, T., Brandslund, I., Nielsen, H.B., Juncker, A.S., Bertalan, M., Levenez, F., Pons, N., Rasmussen, S., Sunagawa, S., Tap, J., Tims, S., Zoetendal, E.G. Brunak, S., Clement, K., Dore, J., Kleerebezem, M., Kristiansen, K., Renault, P., Sicheritz-Ponten, T., de Vos, W.M., Zucker, J.D., Raes, J., Hansen, T., Meta, H.I.T.c., Bork, P., Wang, J., Ehrlich, S.D. and Pedersen, O., 2013. Richness of human gut microbiome correlates with metabolic markers. Nature 500: 541-546. https://doi.org/10.1038/nature12506
-
Li, H., Xi, Y., Xin, X., Tian, H. and Hu, Y., 2020a. Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis. Nutrition and Metabolism 17: 34. https://doi.org/10.1186/s12986-020-00454-y
-
Li, N., Gao, S., Tong, J., Yu, Y., Zhang, Q. and Xu, C., 2020b. Probiotics as a functional food ingredient in allergic diseases: regulation of CD4+ T helper cell differentiation. Critical Reviews in Microbiology 46: 463-474. https://doi.org/10.1080/1040841X.2020.1796578
-
Liu, J., Yang, X., Yu, S. and Zheng, R., 2018. The leptin resistance. Early Life Origins of Health and Disease 1090: 145-163. https://doi.org/10.1007/978-981-13-1286-1_8
-
Louis, S., Tappu, R.M., Damms-Machado, A., Huson, D.H. and Bischoff, S.C., 2016. Characterization of the gut microbial community of obese patients following a weight-loss intervention using whole metagenome shotgun sequencing. PLoS ONE 11: e0149564. https://doi.org/10.1371/journal.pone.0149564
-
Miao, Z.H., Zhou, W.X., Cheng, R.Y., Liang, H.J., Jiang, F.L., Shen, X., Lu, J.H., Li, M. and He, F., 2021. Dysbiosis of intestinal microbiota in early life aggravates high-fat diet induced dysmetabolism in adult mice. BMC Microbiology 21: 209. https://doi.org/10.1186/s12866-021-02263-6
-
Natividad, J.M., Lamas, B., Pham, H.P., Michel, M.L., Rainteau, D., Bridonneau, C., da Costa, G., van Hylckama Vlieg, J., Sovran, B., Chamignon, C., Planchais, J., Richard, M.L., Langella, P., Veiga, P. and Sokol, H., 2018. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nature Communications 9: 2802. https://doi.org/10.1038/s41467-018-05249-7
-
Parker, B.J., Wearsch, P.A., Veloo, A.C.M. and Rodriguez-Palacios, A., 2020. The genus Alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Frontiers in Immunology 11: 906. https://doi.org/10.3389/fimmu.2020.00906
-
Rabot, S., Membrez, M., Blancher, F., Berger, B., Moine, D., Krause, L., Bibiloni, R., Bruneau, A., Gerard, P., Siddharth, J., Lauber, C.L. and Chou, C.J., 2016. High fat diet drives obesity regardless the composition of gut microbiota in mice. Scientific Reports 6: 32484. https://doi.org/10.1038/srep32484
-
Radka, C.D., Frank, M.W., Rock, C.O. and Yao, J., 2020. Fatty acid activation and utilization by Alistipes finegoldii, a representative Bacteroidetes resident of the human gut microbiome. Mol Microbiol 113: 807-825. https://doi.org/10.1111/mmi.14445
-
Reimann, F., Tolhurst, G. and Gribble, F.M., 2012. G-protein-coupled receptors in intestinal chemosensation. Cell Metabolism 15: 421-431. https://doi.org/10.1016/j.cmet.2011.12.019
-
Serino, M., 2019. SCFAs – the thin microbial metabolic line between good and bad. Nature Reviews Endocrinology 15: 318-319. https://doi.org/10.1038/s41574-019-0205-7
-
Shin, J.H., Nam, M.H., Lee, H., Lee, J.S., Kim, H., Chung, M.J. and Seo, J.G., 2018. Amelioration of obesity-related characteristics by a probiotic formulation in a high-fat diet-induced obese rat model. European Journal of Nutrition 57: 2081-2090. https://doi.org/10.1007/s00394-017-1481-4
-
Singer-Englar, T., Barlow, G. and Mathur, R., 2019. Obesity, diabetes, and the gut microbiome: an updated review. Expert Review of Gastroenterology and Hepatology 13: 3-15. https://doi.org/10.1080/17474124.2019.1543023
-
Stojanov, S., Berlec, A. and Strukelj, B., 2020. The influence of probiotics on the Firmicutes/Bacteroidetes ratio in the treatment of obesity and inflammatory bowel disease. Microorganisms 8: 1715. https://doi.org/10.3390/microorganisms8111715
-
Suez, J., Zmora, N., Zilberman-Schapira, G., Mor, U., Dori-Bachash, M., Bashiardes, S., Zur, M., Regev-Lehavi, D., Ben-Zeev Brik, R., Federici, S., Horn, M., Cohen, Y., Moor, A.E., Zeevi, D., Korem, T., Kotler, E., Harmelin, A., Itzkovitz, S., Maharshak, N., Shibolet, O., Pevsner-Fischer, M., Shapiro, H., Sharon, I., Halpern, Z., Segal, E. and Elinav, E., 2018. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174: 1406-1423. https://doi.org/10.1016/j.cell.2018.08.047
-
Valsecchi, C., Tagliacarne, S.C. and Castellazzi, A., 2016. Gut microbiota and obesity. Journal of Clinical Gastroenterology 50: S157-S158. https://doi.org/10.1097/Mcg.0000000000000715
-
Walker, A.W. and Parkhill, J., 2013. Microbiology. Fighting obesity with bacteria. Science 341: 1069-1070. https://doi.org/10.1126/science.1243787
-
Wan, Y., Wang, F., Yuan, J., Li, J., Jiang, D., Zhang, J., Li, H., Wang, R., Tang, J., Huang, T., Zheng, J., Sinclair, A.J., Mann, J. and Li, D., 2019. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. Gut 68: 1417-1429. https://doi.org/10.1136/gutjnl-2018-317609
-
Wang, K., Liao, M., Zhou, N., Bao, L., Ma, K., Zheng, Z., Wang, Y., Liu, C., Wang, W., Wang, J., Liu, S.J. and Liu, H., 2019. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Reports 26: 222-235. https://doi.org/10.1016/j.celrep.2018.12.028
-
Wen, L. and Duffy, A., 2017. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. Journal of Nutrition 147: 1468S-1475S. https://doi.org/10.3945/jn.116.240754
-
World Health Organization (WHO), 2021. Obesity. WHO, Geneva, Switzerland. Available at: https://www.who.int/health-topics/obesity#tab=tab_1
-
Yao, F.F., Jia, R.P., Huang, H., Yu, Y., Mei, L., Bai, L.M., Ding, Y.R. and Zheng, P.Y., 2019. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. Archives of Medical Science 15: 1336-1344. https://doi.org/10.5114/aoms.2019.86611
-
Yao, F.F., Zheng, P.Y., Huang, H., Bai, L.M., Ding, Y.R., Mei, L. and Liu, S.M., 2017. [Effects of Lactobacillus paracasei N1115 combined with fructooligosaccharides on non-alcoholic fatty liver disease induced by high-fat diet in mice]. Zhonghua Gan Zang Bing Za Zhi 25: 927-933. https://doi.org/10.3760/cma.j.issn.1007-3418.2017.12.008
-
Yiu, J.H.C., Chan, K.S., Cheung, J., Li, J., Liu, Y., Wang, Y., Fung, W.W.L., Cai, J., Cheung, S.W.M., Dorweiler, B., Wan, E.Y.F., Tso, P., Xu, A. and Woo, C.W., 2020. Gut Microbiota-associated activation of TLR5 induces apolipoprotein A1 production in the liver. Circulation Research 127: 1236-1252. https://doi.org/10.1161/CIRCRESAHA.120.317362
-
Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S., Kotler, E., Zur, M., Regev-Lehavi, D., Brik, R.B., Federici, S., Cohen, Y., Linevsky, R., Rothschild, D., Moor, A.E., Ben-Moshe, S., Harmelin, A., Itzkovitz, S., Maharshak, N., Shibolet, O., Shapiro, H., Pevsner-Fischer, M., Sharon, I., Halpern, Z., Segal, E. and Elinav, E., 2018. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 174: 1388-1405. https://doi.org/10.1016/j.cell.2018.08.041
Supplementary Materials
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 608 | 182 | 35 |
| PDF Views & Downloads | 297 | 114 | 9 |
Long-term use of Lacticaseibacillus paracasei N1115 from early life alleviates high-fat-diet-induced obesity and dysmetabolism in mice
In: Beneficial MicrobesSearch for other papers by Z.H. Miao in
Current site
Google Scholar
PubMed
Search for other papers by J.N. Wang in
Current site
Google Scholar
PubMed
Search for other papers by X. Shen in
Current site
Google Scholar
PubMed
Search for other papers by Q.Q. Zhou in
Current site
Google Scholar
PubMed
Search for other papers by Y.T. Luo in
Current site
Google Scholar
PubMed
Search for other papers by H.J. Liang in
Current site
Google Scholar
PubMed
Search for other papers by S.J Wang in
Current site
Google Scholar
PubMed
Search for other papers by S.H. Qi in
Current site
Google Scholar
PubMed
Search for other papers by R.Y. Cheng in
Current site
Google Scholar
PubMed
Search for other papers by F. He in
Current site
Google Scholar
PubMed
Obesity has become one of the most serious public health problems worldwide, and an increasing number of studies indicate that the gut microbiota can affect host metabolism. Therefore, the present study was conducted to evaluate whether long-term use of probiotics can alleviate host obesity and metabolism by altering gut microbiota. The high-fat diet (HFD) starting from weaned period led to higher levels of visceral fat and a significantly heavier liver in male mice. Moreover, HFD resulted in disorders of glucose and lipid metabolism, changes in insulin-resistance indices (IR), and an increase in serum insulin and leptin in mice. Of note, 15 weeks use of Lacticaseibacillus paracasei N1115 decreased visceral fat, liver weight, serum levels of insulin and leptin, and IR and alleviated lipid dysmetabolism. HFD resulted in a significant increase in the relative abundance of Bilophila, Lachnoclostridium, and Blautia and may decrease the faecal short-chain fatty acid (SCFA) levels in mice; in turn, treatment with the potential probiotic strain L. paracasei N1115 protected mice from these negative effects. HFD significant impaired the physiology of the host especially in male mice and dramatically changed the composition of host gut microbiota. However, the use of potential probiotic strain, such as L. paracasei N1115, may prevent these impairments due to HFD via effecting the host gut microbiota and SCFA.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 608 | 182 | 35 |
| PDF Views & Downloads | 297 | 114 | 9 |
